ArticleJournal of clinical microbiology2015
Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Intrathecal Antibacterial and Antifungal Therapies.Clinical microbiology reviews · 2020Review
- Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.Antimicrobial agents and chemotherapy · 2017Article
- How to measure the impacts of antibiotic resistance and antibiotic development on empiric therapy: new composite indices.BMJ open · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scattergrams between vancomycin and telavancin demonstrated susceptibility agreement rates of 99.96, 99.65, and 100.00% for Staphylococcus aureus, Enterococcus faecalis, and streptococci, respectively. A single very major error was obtained against E. faecalis, while vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant and teicoplanin-susceptible (VanB phenotype) E. faecalis were responsible for major and minor errors. These results support the use of vancomycin to infer telavancin susceptibility among indicated pathogens, except VISA, which should be tested for telavancin susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.